Back to Scientific and Special Advisors
David Eidelberg, MD - Scientific Advisory Board
Director, Center for Neuroscience
Feinstein Institute for Medical Research
Long Island, New York
David Eidelberg is a graduate of Harvard Medical School. Having completed his residency in neurology at the Harvard-Longwood Area training program, Dr. Eidelberg pursued postdoctoral training in magnetic resonance research at the National Hospital, Queen Square, London. He did additional training in positron emission tomography (PET) at Memorial-Sloan Kettering Cancer Center in New York City. Since 1988, Dr. Eidelberg has served as Director of the Movement Disorders Center and the Functional Brain Imaging Laboratory at North Shore University Hospital. In 1997, he was promoted to the rank of Professor of Neurology and Neurosurgery at New York University (NYU) School of Medicine and in 2000 became the Director of the Center for Neurosciences at the Institute for Medical Research of the North Shore-Long Island Jewish (NS-LIJ) Health System. In 2005, Dr. Eidelberg was named the Feinstein Professor of Neurology at NYU and Vice Chairman of the Department of Medicine at NS-LIJ.
He has been the recipient of numerous grants and awards from the National Institutes of Health and other funding sources. Dr. Eidelberg is internationally recognized for his work in clinical neurosciences and brain imaging, having delivered over 150 invited lectures in North America, Europe, and Asia over the past five years. He is the author or co-author of over 300 scientific publications and serves on the editorial boards of Neurology (1995-2001), Movement Disorders (1999-2003), Journal of Nuclear Medicine (1999-Present), Current Opinion in Neurology (2001-2004), and Clinical Neuroscience Research (2004-Present).
Dr. Eidelberg's current research interests include using neuroimaging techniques to study of disease mechanisms in Parkinson's disease (PD) and related movement disorders. A major contribution of his work has been the development of an integrated approach utilizing in vivo radiotracer measurements, network quantification, and behavioral psychophysics as a means of determining changes in functional brain circuitry during novel therapies for PD.
